GlaxoSmithKline's (GSK) Advair HFA Inhalation Aerosol is Now Available
Advair HFA Inhalation Aerosol, a new formulation combining fluticasone propionate and salmeterol in a metered-dose inhaler (MDI) delivery device, is now available in pharmacies nationwide. Advair, a medicine used in the treatment of asthma, became available in 2001 as a dry-powdered inhaler known as Advair Diskus.
Advair HFA was developed and is marketed by GlaxoSmithKline (NYSE: GSK), a research-based pharmaceutical and a world leader in respiratory care. GlaxoSmithKline is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
Create E-mail AlertRelated Categories
Corporate NewsStocks Mentioned
-0.31Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
